SCHEMBL31748652

SCHEMBL31748652

O=c1cc[nH]cc1-c1ccc[nH]c1=O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AURKA O14965 2/20 0.41
DAO P14920 1/20 0.41
AURKB Q96GD4 1/20 0.41
INCENP Q9NQS7 1/20 0.41
NPC1 O15118 2/20 0.39
GBA1 P04062 1/20 0.39
CHRNB4 P30926 1/20 0.37
CHRNA3 P32297 1/20 0.37
ALDH1A1 P00352 4/20 0.37
KMT2A Q03164 3/20 0.37
MCL1 Q07820 1/20 0.37
NAPRT Q6XQN6 1/20 0.37
KDM4E B2RXH2 3/20 0.36
CYP1A2 P05177 1/20 0.36
HPGD P15428 1/20 0.36
RAB9A P51151 1/20 0.36
ATM Q13315 1/20 0.36
ERAP1 Q9NZ08 1/20 0.36
GAA P10253 1/20 0.34
CYP1A1 P04798 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4480940 0.81 KMT2A (0.50) CHRNB4CHRNA3ALDH1A1KMT2AIDO1
SCHEMBL2101505 0.81 AURKA (0.56) AURKADAOAURKBINCENPNPC1
SCHEMBL20940147 0.70 DAO (0.38) AURKADAOAURKBINCENPNPC1
SCHEMBL11055567 0.69 ALDH1A1 (0.45) CHRNB4CHRNA3ALDH1A1KMT2AKDM4E
SCHEMBL28563542 0.68 NPC1 (0.47) AURKADAOAURKBINCENPNPC1
SCHEMBL2022467 0.67 PARP1 (0.36) AURKAAURKBINCENPALDH1A1KMT2A
SCHEMBL149989 0.67 MAPT (0.57) AURKADAOAURKBINCENPNPC1
Hydrochloric Acid SCHEMBL29878602 0.65 MAPT (0.55) AURKADAOAURKBINCENPNPC1
SCHEMBL6192864 0.65 HDAC4 (0.38) CHRNB4CHRNA3ALDH1A1KMT2AMAPT
SCHEMBL11465256 0.65 MAPT (0.60) AURKADAOAURKBINCENPNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250388543-A1 HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN VERTEX PHARMACEUTICALS INCORPORATED (US) 2025-12-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250388543-A1 HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN SCN8A, SCN1B, SCN3A AURKA 4587/4885DAO 2472/4885AURKB 4493/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.